Furthermore, basal protein expression of one of these genes, CITED2, correlated with THZ1 sensitivity, suggesting that CITED2 may serve as a possible biomarker of response to CDK7 inhibitors in the treatment of all breast cancer subtypes. The gene discussed is CITED2; the disease is breast carcinoma.